How to judge the validity of cancer medical treatment which made a target a fusion gene of a KIF5B gene and a RET gene, and the fusion gene

Japanese Patent JP6032616

B2

In order to identify a gene that can serve as an indicator for predicting the effectiveness of a drug treatment of cancer and to provide a novel method for predicting the effectiveness of a drug treatment targeting said gene, lung adenocarcinomas were subjected to whole-transcriptome sequencing. As a result, in-frame fusion transcripts between the KIF5B gene and the RET gene were identified. The KIF5B-RET gene fusions were detected in 6 out of 319 (2%) LADC specimens from Japanese individuals and 1 out of 80 (1%) LADC specimens from U.S.A. individuals. None of the seven subjects revealed known activating mutations such as EGFR, KRAS or ALK oncogenes; thus, said gene fusions were found to be responsible mutations (driver mutations) for oncogenesis. Since said gene fusions are considered to induce constitutive activation of RET tyrosine kinase protein, it was found that treatments with RET tyrosine kinase inhibitors are effective in patients with detection of said gene fusions.

Takashi Kono
Koji Tsuta

JP2013526964A

November 30, 2016

August 03, 2012

Click for automatic bibliography generation  

National Cancer Research Center
lsip fund management limited liability company

C07K19/00; C07K14/82; C12N15/09; C12Q1/68; G01N33/53

JP2010509289A

WO2010000012A1
WO2007049624A1
WO2012053606A1

Shinjiro Ono
Yasushi Kobayashi
Shigeo Takeuchi
Osamu Yamamoto
Norihiro Fukasawa
Ichinomiya

Previous Patent: Jam which is excellent in health maintenance, a skill, and sales promotion nature

Next Patent: REACTIVE INJECTION MOLDING METHOD